Sparks - SIGA Technologies

SIGA Technologies has in-licensed a new preclinical portfolio of monoclonal antibodies (mAbs) from the Vanderbilt University Medical Center, to be developed as a potential treatment for a range of orthopoxviruses. We expect this to complement the company’s marketed antiviral treatment, TPOXX, which is approved for smallpox in the US and for all orthopoxviruses in Europe. The financial terms of the deal remain undisclosed.

The mAb programme has reported encouraging preclinical data and has secured funding from the US Department of Defense to advance R&D efforts through Phase I clinical development. SIGA plans to develop the programme as either monotherapy or in combination with TPOXX. The company already has an established relationship with US government agencies, with R&D for its TPOXX programme and subsequent prophylactic label expansion backed by the Biomedical Advanced Research and Development Authority.